title: Traumatic optic neuropathy and second optic nerve injuries.
abstract: OBJECTIVE
  Current controversy about the primary treatment of traumatic optic neuropathy (TON) has anchored on final vision following injury, but, to our knowledge, no study has examined the effect of different treatments on regaining and protecting optic nerve reserve or on the outcome of second optic nerve injuries.
  
  
  OBJECTIVE
  To assess vision improvement in patients treated by various methods who have a second incidence of TON.
  
  
  METHODS
  Retrospective medical record review of 12 patients with a second TON seen in an 18-year period (mean follow-up, 11.3 months) at a single tertiary care oculoplastic practice.
  
  
  METHODS
  Observation, high-dose corticosteroids, optic nerve decompression, or high-dose corticosteroids plus optic nerve decompression.
  
  
  METHODS
  Change in vision on the Snellen eye chart. RESULTS All second TON events involved the same-side optic nerve as initially injured, and with observation alone, corticosteroids, or corticosteroids and partial optic canal decompression, all patients had vision improvement after their initial injury (P = .004). However, following the second optic nerve injury, most patients' vision fell to the pretreatment level of the first injury, and subsequent management of the second injury with corticosteroids and/or optic canal decompression provided little or no vision return (P = .05). In contrast, optic canal decompressions performed for 91 primary TON injuries resulted in 82.4% having some degree of vision improvement.
  
  
  CONCLUSIONS
  Patients with TON may have a second optic nerve insult, and vision recovery from the second event may be limited regardless of primary treatment choice.
authors.affiliation: Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas.
authors.forename: William Marshall
authors.initials: WM
authors.lastname: Guy
authors.affiliation: Weill-Cornell College of Medicine, The Methodist Hospital, Houston, Texas3Department of Head and Neck Surgery, MD Anderson Cancer Center, Houston, Texas4Department of Ophthalmology, Baylor College of Medicine, Houston, Texas5Department of Plastic Surgery.
authors.forename: Charles N S
authors.initials: CN
authors.lastname: Soparkar
authors.affiliation: Weill-Cornell College of Medicine, The Methodist Hospital, Houston, Texas.
authors.forename: Eugene L
authors.initials: EL
authors.lastname: Alford
authors.affiliation: Department of Ophthalmology, Baylor College of Medicine, Houston, Texas5Department of Plastic Surgery, Baylor College of Medicine, Houston, Texas6Plastic Eye Surgery Associates, PLLC, Houston, Texas.
authors.forename: James R
authors.initials: JR
authors.lastname: Patrinely
authors.affiliation: Department of Head and Neck Surgery, MD Anderson Cancer Center, Houston, Texas6Plastic Eye Surgery Associates, PLLC, Houston, Texas.
authors.forename: Mirwat S
authors.initials: MS
authors.lastname: Sami
authors.affiliation: Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas.
authors.forename: Robert B
authors.initials: RB
authors.lastname: Parke
mesh_terms: D000328:Adult; D019299:Decompression, Surgical / Q000379:methods*; D004305:Dose-Response Relationship, Drug; D004724:Endoscopy / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D008875:Middle Aged; D009900:Optic Nerve / Q000473:pathology / Q000601:surgery*; D020221:Optic Nerve Injuries / Q000175:diagnosis / Q000628:therapy*; D012008:Recurrence; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D005938:Glucocorticoids; D008775:Methylprednisolone